Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNST NASDAQ:DRNA NASDAQ:INVA NASDAQ:LGND NASDAQ:PCRX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ADRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AINVAInnoviva$17.27+0.1%$19.22$16.52▼$22.00$1.09B0.4765,889 shs760,832 shsLGNDLigand Pharmaceuticals$181.65+0.5%$167.66$93.58▼$186.48$3.54B0.95166,914 shs156,792 shsPCRXPacira BioSciences$22.87+0.4%$25.37$16.00▼$27.64$1.02B0.4494,614 shs246,471 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVAInnoviva+0.12%-0.46%-10.89%-11.75%-14.55%LGNDLigand Pharmaceuticals+0.49%+2.21%+9.82%+30.59%+69.51%PCRXPacira BioSciences+0.44%+2.33%-12.27%+5.93%+37.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNSTConstellation Pharmaceuticals$33.99$33.89$17.00▼$39.30$1.63B2.59940,325 shsN/ADRNADicerna Pharmaceuticals$38.22$38.12$19.06▼$40.14$2.99B0.81.34 million shsN/AINVAInnoviva$17.27+0.1%$19.22$16.52▼$22.00$1.09B0.4765,889 shs760,832 shsLGNDLigand Pharmaceuticals$181.65+0.5%$167.66$93.58▼$186.48$3.54B0.95166,914 shs156,792 shsPCRXPacira BioSciences$22.87+0.4%$25.37$16.00▼$27.64$1.02B0.4494,614 shs246,471 shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNSTConstellation Pharmaceuticals0.00%0.00%0.00%0.00%0.00%DRNADicerna Pharmaceuticals0.00%0.00%0.00%0.00%0.00%INVAInnoviva+0.12%-0.46%-10.89%-11.75%-14.55%LGNDLigand Pharmaceuticals+0.49%+2.21%+9.82%+30.59%+69.51%PCRXPacira BioSciences+0.44%+2.33%-12.27%+5.93%+37.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNSTConstellation Pharmaceuticals 0.00N/AN/AN/ADRNADicerna Pharmaceuticals 0.00N/AN/AN/AINVAInnoviva 2.71Moderate Buy$37.60117.72% UpsideLGNDLigand Pharmaceuticals 2.71Moderate Buy$176.50-2.84% DownsidePCRXPacira BioSciences 2.43Hold$33.4046.04% UpsideCurrent Analyst Ratings BreakdownLatest PCRX, DRNA, INVA, LGND, and CNST Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025INVAInnovivaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy10/8/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/8/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/30/2025INVAInnovivaThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell$17.009/27/2025INVAInnovivaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025LGNDLigand PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025PCRXPacira BioSciencesWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D)9/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/2/2025LGNDLigand PharmaceuticalsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$160.00 ➝ $175.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNSTConstellation PharmaceuticalsN/AN/AN/AN/A$8.63 per shareN/ADRNADicerna Pharmaceuticals$164.31M18.17N/AN/A$1.84 per share20.77INVAInnoviva$358.71M3.03$3.43 per share5.04$11.03 per share1.57LGNDLigand Pharmaceuticals$187.58M18.98$1.61 per share112.50$43.95 per share4.13PCRXPacira BioSciences$700.97M1.47$4.34 per share5.27$16.86 per share1.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNSTConstellation Pharmaceuticals-$126.36M-$2.81N/AN/AN/AN/A-33.12%-29.92%N/ADRNADicerna Pharmaceuticals-$112.75M-$1.63N/AN/AN/A-64.53%-103.08%-16.58%N/AINVAInnoviva$23.39M$0.3155.7111.14N/A10.44%18.67%9.92%11/5/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A48.96N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)PCRXPacira BioSciences-$99.56M-$2.78N/A8.90N/A-18.08%13.29%6.61%11/5/2025 (Estimated)Latest PCRX, DRNA, INVA, LGND, and CNST EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025LGNDLigand Pharmaceuticals$1.96N/AN/AN/A$58.71 millionN/A11/5/2025Q3 2025INVAInnoviva$0.46N/AN/AN/A$91.31 millionN/A11/5/2025Q3 2025PCRXPacira BioSciences$0.66N/AN/AN/A$182.86 millionN/A8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/5/2025Q2 2025PCRXPacira BioSciences$0.73$0.74+$0.01-$0.11$183.11 million$181.10 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNSTConstellation PharmaceuticalsN/AN/AN/AN/AN/ADRNADicerna PharmaceuticalsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/APCRXPacira BioSciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNSTConstellation PharmaceuticalsN/A15.3915.39DRNADicerna PharmaceuticalsN/A2.462.46INVAInnoviva0.362.642.44LGNDLigand PharmaceuticalsN/A5.455.21PCRXPacira BioSciences0.502.381.91Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNSTConstellation PharmaceuticalsN/ADRNADicerna Pharmaceuticals78.91%INVAInnoviva99.12%LGNDLigand Pharmaceuticals91.28%PCRXPacira BioSciences99.73%Insider OwnershipCompanyInsider OwnershipCNSTConstellation Pharmaceuticals43.70%DRNADicerna Pharmaceuticals10.20%INVAInnoviva2.25%LGNDLigand Pharmaceuticals7.00%PCRXPacira BioSciences6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNSTConstellation Pharmaceuticals15447.92 millionN/ANot OptionableDRNADicerna Pharmaceuticals30278.13 million70.16 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionablePCRXPacira BioSciences72044.93 million42.06 millionOptionablePCRX, DRNA, INVA, LGND, and CNST HeadlinesRecent News About These CompaniesEasterly Investment Partners LLC Boosts Holdings in Pacira BioSciences, Inc. $PCRXOctober 17 at 7:11 AM | marketbeat.comKLP Kapitalforvaltning AS Increases Stake in Pacira BioSciences, Inc. $PCRXOctober 16 at 3:15 AM | marketbeat.comPacira BioSciences (NASDAQ:PCRX) Given "Sell (D)" Rating at Weiss RatingsOctober 10, 2025 | marketbeat.comPacira BioSciences, Inc. $PCRX Shares Bought by Gagnon Securities LLCOctober 8, 2025 | marketbeat.comGagnon Advisors LLC Has $5.10 Million Position in Pacira BioSciences, Inc. $PCRXOctober 8, 2025 | marketbeat.comRobeco Institutional Asset Management B.V. Has $1.29 Million Holdings in Pacira BioSciences, Inc. $PCRXOctober 8, 2025 | marketbeat.comGreenwood Capital Associates LLC Takes $314,000 Position in Pacira BioSciences, Inc. $PCRXOctober 4, 2025 | marketbeat.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 3, 2025 | globenewswire.comPacira BioSciences, Inc. (NASDAQ:PCRX) Given Average Rating of "Moderate Buy" by AnalystsSeptember 26, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $11.54 Million Stock Holdings in Pacira BioSciences, Inc. $PCRXSeptember 23, 2025 | marketbeat.comPacira BioSciences (PCRX): Evaluating Valuation After Recent Share Price MomentumSeptember 17, 2025 | finance.yahoo.comPacira reports inducement grants under Nasdaq listing ruleSeptember 6, 2025 | msn.comPacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 5, 2025 | globenewswire.comMarcelo Bigal Sells 4,912 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) StockAugust 12, 2025 | insidertrades.comPacira BioSciences, Inc. (NASDAQ:PCRX) Q2 2025 Earnings Call TranscriptAugust 7, 2025 | msn.comPacira (PCRX) Q2 Revenue Rises 1.7%August 6, 2025 | aol.comAPacira outlines narrowed $730M–$750M revenue guidance and increased margin targets as J&J ZILRETTA partnership takes shapeAugust 6, 2025 | msn.comPacira BioSciences, Inc. (PCRX) Q2 2025 Earnings Call TranscriptAugust 6, 2025 | seekingalpha.comPacira BioSciences, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 6, 2025 | seekingalpha.comPacira reports Q2 EPS 74c, consensus 71cAugust 6, 2025 | msn.comPacira (PCRX) Tops Q2 Earnings EstimatesAugust 6, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimePCRX, DRNA, INVA, LGND, and CNST Company DescriptionsConstellation Pharmaceuticals NASDAQ:CNSTConstellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics to address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidates include Pelabresib that is in Phase 3 clinical trials for the treatment of patients with myelofibrosis in combination with ruxolitinib. It is also developing CPI-0209 that is in Phase 1 dose escalation portion of a Phase 1/2 clinical trial to treat solid tumors; and CPI-482, which is in preclinical stage for cancer patients. The company was formerly known as Epigenetix, Inc. and changed its name to Constellation Pharmaceuticals, Inc. in March 2008. Constellation Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.Dicerna Pharmaceuticals NASDAQ:DRNADicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The firm uses its proprietary GalXC RNAi technology platform to build a pipeline in these therapeutic areas. The company was founded by Douglas M. Fambrough III, Mark A. Behlke, Roberto Guerciolini, James Craig Jenson, and John J. Rossi in October 2006 and is headquartered in Lexington, MA.Innoviva NASDAQ:INVA$17.27 +0.02 (+0.12%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$16.87 -0.40 (-2.32%) As of 10/17/2025 04:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Ligand Pharmaceuticals NASDAQ:LGND$181.65 +0.88 (+0.49%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$181.76 +0.10 (+0.06%) As of 10/17/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.Pacira BioSciences NASDAQ:PCRX$22.87 +0.10 (+0.44%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$22.86 -0.02 (-0.07%) As of 10/17/2025 04:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
